Takeda Pharmaceutical Co. v. Painters Fund


(U.S., filed March 27, 2020): Urging the Court to review whether the chain of causation between a manufacturer’s allegedly false statements and end payments for prescription drugs is too attenuated to satisfy RICO’s proximate cause requirement.  Also, to address whether everyone who pays for a product with an alleged latent risk or defect suffer injury sufficient to confer Article III standing.

Court denied cert

Latest News

View all news

SCOTUS Should Affirm Federal Law Supremacy With FDA Authority Case

The U.S. Supreme Court has a chance to rein in state court rulings that impose liability on pharmaceutical companies that go beyond, and even contradict, the federal regulatory process of the FDA, according to Tiger Joyce, president of the American Tort Reform Association. He explains why it is imperative the high court review a case involving Janssen Pharmaceuticals.